CTRI/2019/07/020142
Active, not recruiting
未知
Health expenditure on breast cancer treatment in women: a study from public sector tertiarycancer centre
Womens cancer initiative0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Sponsor
- Womens cancer initiative
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Pathologically confirmed new invasive breast cancer cases
- •2\) Non\-metastatic invasive breast cancer (AJCC 8th edition)
- •3\) Intending to receive entire treatment at TMC
- •4\) Planned for multi\-modality treatment comprising of surgery, chemotherapy and radiotherapy with or without hormone therapy or targeted therapy
- •5\) Age \> 18 years
- •6\) Patient willing to provide all estimates of expenditure before and after coming to the tertiary hospital.
- •7\) Patient willing to share relevant socio\-demographic information.
- •8\) Willing to fill or respond to QOL instruments.
Exclusion Criteria
- •1\) Unable or unwilling to give written informed consent
- •2\) Inability to follow up after treatment completion.
- •3\) Not willing for follow up till 2 years.
- •4\) Recurrent or progressive disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A multinational study to evaluate financial difficulties of patient for breast cancer treatment.CTRI/2024/01/062071Tata Memorial Centre
Recruiting
Not Applicable
Estimation of Willingness-to-Pay for breast cancer treatments through Contingent Valuation Method in Japanese breast cancer patients(JCOG1709A)1)Unilateral breast cancer patients who fulfill either i) or ii) below i)Primary breast cancer of clinical stage 0 through III for which surgery and /or chemotherapy and / or radiotherapy has been completed as initial treatment and that is currently undergoing regular follow-up observations or postoperative endocrine therapy ii)Undergoing endocrine therapy or first-line through third-line chemotherapy for metastatic or recurrent cancer for at least 2 monthsJPRN-UMIN000037445Japan Clinical Oncology Group (JCOG)1,764
Not yet recruiting
Not Applicable
A study on the impact of pharmaceutical care on breast cancer patientsHealth Condition 1: C50- Malignant neoplasm of breastCTRI/2020/07/026688Self funded
Completed
Not Applicable
Specialist nurse-led clinics for breast cancer patientsBreast cancerCancerMalignant neoplasm of breastISRCTN54211123HS R&D Regional Programme Register - Department of Health (UK)354
Completed
Phase 2
Problem-solving therapy for breast cancer patients undergoing chemotherapy on an outpatient basisBreast cancerJPRN-UMIN000011190Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University100